Pipeline by Mechanism and Stage

Every material GLP-1 and adjacent obesity asset plotted by mechanism family and development stage, with bubble size scaled to placebo-adjusted weight loss.

GLP-1 (mono)Oral GLP-1Oral non-peptide GLP-1Dual GLP-1/GIPDual GLP-1/glucagonTriple (GLP-1/GIP/glucagon)Amylin mono or comboAntibody-peptide conjugateMC4R agonistCB1 antagonistFGF21 analog (MASH-adjacent)

Updated at May 2026

Injectable Pipeline: Weight Loss vs Trial Duration

Placebo-adjusted weight loss vs trial duration for injectable obesity candidates, color-coded by mechanism. Upper-right is max efficacy; tirzepatide at 72 weeks is the approved benchmark.

Triple (GLP-1/GIP/glucagon)Dual GLP-1/GIPAmylin + GLP-1 comboDual GLP-1/glucagonAntibody-peptide conjugateGLP-1Amylin monoAmylin + GLP-1 co-agonist

Updated at 2026-05-22

Oral GLP-1 and Adjacent Oral Candidates

Oral GLP-1 and adjacent oral mechanism candidates ranked by stage. Orforglipron (Lilly) is the first oral non-peptide GLP-1, removing the SNAC enhancer requirement.

Drug	Sponsor	Mechanism	Formulation	Weight loss	Duration	Stage	Status
Rybelsus (oral semaglutide)	Novo Nordisk	GLP-1	Daily oral peptide + SNAC absorption enhancer	4.0%	26-68 wk	Approved	T2D since 2019; oral Wegovy obesity launched Jan 2026
Orforglipron	Eli Lilly	Non-peptide GLP-1	Daily oral small molecule (no absorption enhancer required)	9.1%	72 wk	FDA decision Q2 2026	First oral non-peptide GLP-1 RA. ATTAIN-1 readout late 2025
Aleniglipron	Structure + Roche	GLP-1	Oral small molecule (with Roche licensing partner)	11.0%	36 wk	Phase 2 (Phase 3 planned)	Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted
VK2735 (oral)	Viking	Dual GLP-1/GIP	Daily oral	10.9%	13 wk	Phase 2 hit (Phase 3 planned)	VENTURE-Oral Ph2 mid-stage data; injectable VK2735 ahead in Phase 3
ECC5004	AstraZeneca	GLP-1	Oral small molecule	7.0%	16 wk	Phase 2	Building third-tier oral franchise
TERN-601	Terns	GLP-1	Oral small molecule	5.0%	12 wk	Phase 2	MASH and obesity combination strategy
K-757 / KAL-1199	Kallyope	GLP-1	Oral peptide (gut-restricted)	4.0%	12 wk	Phase 2	Gut-restricted approach minimizes systemic exposure
ARD-101	Aardvark	Bitter receptor agonist	Oral	3.0%	12 wk	Phase 2	Prader-Willi syndrome and obesity adjacencies
Bivamelagon	Rhythm	Oral MC4R agonist	Oral small molecule	7.0%	14 wk	Phase 2	Phase 2 BMI reduction comparable to IMCIVREE (setmelanotide)

Updated at 2026-05-22

Long-Acting and Differentiated Dosing

GLP-1 candidates targeting dosing intervals beyond the once-weekly standard. MariTide (Amgen) is the only Phase 3 entry; the rest are early-stage.

Drug	Sponsor	Mechanism	Dosing interval	Stage	Rationale
MariTide	Amgen	Antibody-peptide conjugate (GLP-1 agonist + GIPR antagonist)	Monthly or less frequent	Phase 3	Conjugate chemistry from oncology ADC playbook enables extended half-life
MariTide Q-monthly variants	Amgen	Antibody-peptide conjugate	Q-monthly investigational	Phase 1	Conjugate design supports further interval extension if safety holds
Tirzepatide depot (exploratory)	Eli Lilly	Dual GLP-1/GIP (peptide depot)	Bi-weekly or monthly target	Preclinical / undisclosed	Existing tirzepatide molecule reformulated for longer release
Long-acting semaglutide	Novo Nordisk	Extended half-life GLP-1	Bi-weekly to monthly target	Preclinical	Same semaglutide active with engineered half-life extension
TransCon GLP-1 (exploratory)	Ascendis Pharma	TransCon prodrug platform	Weekly to monthly target	Preclinical	Sustained-release platform validated in growth hormone (Skytrofa)

Updated at 2026-05-22

Late-Stage Phase 3 Readouts

Phase 3 obesity and GLP-1 trial readouts through 2028 by company, mechanism, indication, and target window. The catalyst calendar driving pipeline valuations.

Readout	Company	Asset	Mechanism	Indication	Trial	Note
2026-Q2	Eli Lilly(LLY)	Orforglipron	Oral non-peptide GLP-1	Obesity	ATTAIN program	First oral non-peptide GLP-1 RA. ATTAIN-1 reported 11.2% mean weight loss at 72 weeks (high dose) vs 2.1% placebo. FDA decision Q2 2026.
2026-H1	Eli Lilly(LLY)	Tirzepatide	Dual GLP-1/GIP	MACE in T2D	SURPASS-CVOT readout context	Label expansion for cardiovascular outcomes in T2D expected H1 2026. Triggers Medicare Part D coverage for tirzepatide CV indication.
2026-H2	Novo Nordisk(NVO)	CagriSema	Amylin + GLP-1 combo	Obesity	REDEFINE-1	Cagrilintide 2.4mg + semaglutide 2.4mg, once-weekly injection. 68-week Phase 3a (NEJM): ~22.7% mean weight loss. Filed December 2025.
2026	Altimmune(ALT)	Pemvidutide	GLP-1 / glucagon dual	MASH (IMPACT Phase 2b)	IMPACT	MASH-first positioning. Phase 2b MASH IMPACT data expected 2026.
2026-late	Amgen(AMGN)	MariTide	Antibody-peptide conjugate (GLP-1 agonist + GIPR antagonist)	Obesity	MARITIME program	Monthly or less frequent dosing. Phase 3 readout expected late 2026, BLA filing late 2026 to early 2027.
2026-2027	Roche(RHHBY)	CT-388	Dual GLP-1/GIP	Obesity	Phase 3 (initiating)	Carmot acquisition asset. Phase 2: ~23% placebo-adjusted weight loss at 48 weeks. Phase 3 initiating in 2026.
2026-2027	Boehringer + Zealand(ZEAL.CO)	Survodutide	GLP-1 / glucagon dual	MASH and obesity	SYNCHRONIZE program	Partnered with Boehringer Ingelheim (private). MASH and obesity readouts 2026 to 2027.
2026-2027	Eli Lilly(LLY)	Retatrutide	Triple GLP-1/GIP/glucagon	Obesity, T2D, MASH	TRIUMPH program	First triple agonist in Phase 3. Phase 2 weight loss approaching 24-26%, comparable to bariatric surgery. Multiple TRIUMPH trials reading out 2026 to 2027.
2026	AstraZeneca(AZN)	AZD6234	Oral amylin agonist	Obesity	APRICUS Phase 2b	Phase 2b completing 2026. Amylin pathway differentiation for GLP-1-intolerant patients or as combination partner.
2027	Novo Nordisk(NVO)	Amycretin	GLP-1 + amylin co-agonist	Obesity	Phase 3	Next-generation Novo asset. Phase 1 readouts very encouraging; Phase 3 starting 2026, readouts expected 2027.
2027	Viking Therapeutics(VKTX)	VK2735 (injectable)	Dual GLP-1/GIP	Obesity	VANQUISH-1 Phase 3	Phase 2 injectable hit obesity endpoint; Phase 3 ongoing. M&A-prone given big-pharma demand.
2027	Structure Therapeutics(GPCR)	Aleniglipron	Oral small-molecule GLP-1	Obesity and T2D	ACCESS-3 and ACCESS-T2D	Roche licensing partnership ($100M) for additional assets. Phase 2 high-dose 11%+ placebo-adjusted at 36 weeks.
2027-2028	Akero(AKRO)	Efruxifermin	FGF21 analog	MASH	SYMMETRY	MASH-adjacent (non-GLP-1). Novo Nordisk acquiring Akero for $5.2B; positions MASH as combinable with GLP-1.

Updated at 2026-05-31

Survodutide Phase 3 Enrollment Progress

Cumulative monthly enrollment across the three Boehringer Ingelheim + Zealand Phase 3 survodutide trials (obesity, T2D, and MASH), with dashed per-trial targets.

Updated at 2026-05-28

FDA Decision Calendar

Anticipated FDA approval, label-expansion, and rulemaking decisions for GLP-1 and obesity assets through 2027, with recent past decisions shown for context.

Expected	Company	Asset	Indication	Type	Status	Note
2024-03	Novo Nordisk(NVO)	Wegovy (semaglutide 2.4mg)	MACE risk reduction in CVD + overweight/obesity	Label Expansion	Approved	SELECT trial: 20% MACE reduction. Triggered Medicare Part D coverage for cardiovascular indication.
2024-12	Eli Lilly(LLY)	Zepbound (tirzepatide)	Moderate-to-severe OSA in obesity	Label Expansion	Approved	SURMOUNT-OSA trial. Opened sleep medicine and pulmonology prescriber base.
2025-01	Novo Nordisk(NVO)	Ozempic (semaglutide 1mg)	Chronic kidney disease in T2D	Label Expansion	Approved	FLOW trial: 24% reduction in composite kidney endpoint.
2026-03	Rhythm(RYTM)	IMCIVREE (setmelanotide)	Acquired hypothalamic obesity	Label Expansion	Approved	First FDA-approved therapy for acquired hypothalamic obesity. MC4R agonist, narrow indication.
2026-Q2	Eli Lilly(LLY)	Orforglipron	Chronic weight management	New Drug Approval	PDUFA pending	First oral non-peptide GLP-1 receptor agonist. ATTAIN-1: 11.2% mean weight loss at 72 weeks vs 2.1% placebo.
2026-H1	Eli Lilly(LLY)	Mounjaro (tirzepatide)	MACE risk reduction in T2D	Label Expansion	Expected	Lilly guidance H1 2026. Triggers Medicare Part D coverage for tirzepatide CV indication.
2026-06-29	FDA	503B bulk substances proposal	Compounding crackdown	Rulemaking	Comment open	Public comment closes June 29, 2026 on proposal to remove semaglutide, tirzepatide, liraglutide from 503B bulks list. Effectively ends large-scale compounding.
2026-07-01	CMS	Medicare GLP-1 Bridge	Access program launch	Coverage Program	Scheduled	$50/month copay for eligible Medicare beneficiaries with covered cardiovascular indication. Runs through December 31, 2027.
2026-H2	Novo Nordisk(NVO)	Semaglutide	MASH	Label Expansion	Filed (sNDA)	ESSENCE Phase 3 published 2025. FDA decision date to verify; expected 2026 to 2027.
2026-H2	Novo Nordisk(NVO)	CagriSema (cagrilintide + semaglutide)	Chronic weight management	New Drug Approval	Filed (Dec 2025)	Once-weekly injection combining amylin + GLP-1. 68-week Phase 3a NEJM: about 22.7% mean weight loss.
2026-Q4	Eli Lilly(LLY)	Zepbound (tirzepatide)	Adolescent obesity (12 to 17)	Label Expansion	Late-stage	Late-stage adolescent trials reading out 2026. Wegovy is the only currently-approved adolescent option.
2026-2027	Roche(RHHBY)	CT-388	Chronic weight management	Phase 3 advance	Phase 3 start 2026	Carmot-origin dual GLP-1/GIP. Phase 2 showed about 23% placebo-adjusted weight loss at 48 weeks.
2026-late	Amgen(AMGN)	MariTide	Chronic weight management	Phase 3 readout	Phase 3 ongoing	Differentiated antibody-peptide conjugate, monthly or less frequent dosing. BLA filing late 2026 to early 2027.
2026	Altimmune(ALT)	Pemvidutide	MASH (IMPACT Phase 2b)	Phase 2b readout	Phase 2b data 2026	GLP-1/glucagon dual agonist. MASH-first positioning differentiates from obesity-focused peers.
2027-01-01	CMS	Semaglutide (Ozempic, Wegovy, Rybelsus)	IRA negotiated price effective	Pricing	Scheduled	IRA Medicare Drug Price Negotiation maximum fair price takes effect Jan 1, 2027.
2027-late	Boehringer + Zealand(ZEAL.CO)	Survodutide	MASH and obesity	Phase 3 readout	Phase 3 ongoing	Dual GLP-1/glucagon partnered with Boehringer Ingelheim (private). MASH and obesity readouts expected 2026 to 2027.

Updated at 2026-05-31

Pipeline by Mechanism and Stage

Injectable Pipeline: Weight Loss vs Trial Duration

Oral GLP-1 and Adjacent Oral Candidates

Long-Acting and Differentiated Dosing

Late-Stage Phase 3 Readouts

Survodutide Phase 3 Enrollment Progress

FDA Decision Calendar

Ask Sterling